Why the drug development pipeline is not delivering better medicines
Naci, H.
, Carter, A. W. & Mossialos, E.
(2015).
Why the drug development pipeline is not delivering better medicines.
BMJ,
351,
https://doi.org/10.1136/bmj.h5542
Despite the large number of new medicines entering the market every year, the vast majority offer few clinical advantages for patients over existing alternatives. Governments and pharmaceutical companies share the responsibility for this innovation deficit in the sector.
| Item Type | Article |
|---|---|
| Copyright holders | © 2015 British Medical Journal Publishing Group |
| Departments | LSE > Research Centres > LSE Health |
| DOI | 10.1136/bmj.h5542 |
| Date Deposited | 29 Oct 2015 |
| URI | https://researchonline.lse.ac.uk/id/eprint/64220 |
Explore Further
- http://www.lse.ac.uk/health-policy/people/huseyin-naci-phd-mhs.aspx (Author)
- https://www.scopus.com/pages/publications/84948401753 (Scopus publication)
- http://www.bmj.com/thebmj (Official URL)
ORCID: https://orcid.org/0000-0002-7192-5751
ORCID: https://orcid.org/0000-0001-8664-9297